LivaNova PLC (NASDAQ:LIVN) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC grew its position in LivaNova PLC (NASDAQ:LIVN) by 18.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,611 shares of the company’s stock after acquiring an additional 5,990 shares during the period. SG Americas Securities LLC owned about 0.07% of LivaNova worth $1,946,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in LIVN. Morgan Stanley increased its position in LivaNova by 699.0% during the 4th quarter. Morgan Stanley now owns 1,649,861 shares of the company’s stock worth $91,633,000 after purchasing an additional 1,443,379 shares during the period. Alliancebernstein L.P. raised its position in LivaNova by 143.0% in the second quarter. Alliancebernstein L.P. now owns 2,225,363 shares of the company’s stock worth $114,450,000 after acquiring an additional 1,309,486 shares in the last quarter. Norges Bank purchased a new position in shares of LivaNova in the 4th quarter valued at about $50,390,000. Ameriprise Financial Inc. increased its holdings in shares of LivaNova by 96.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock valued at $48,471,000 after purchasing an additional 449,136 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in shares of LivaNova by 6.4% in the first quarter. BlackRock Inc. now owns 7,271,165 shares of the company’s stock valued at $316,877,000 after purchasing an additional 436,552 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on LIVN. Robert W. Baird upped their target price on shares of LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a research report on Thursday, February 22nd. Mizuho restated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price objective on shares of LivaNova in a report on Wednesday, March 20th. Finally, Barclays upped their target price on LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $64.40.

LivaNova Stock Performance

LivaNova stock opened at $55.87 on Thursday. LivaNova PLC has a fifty-two week low of $41.87 and a fifty-two week high of $59.86. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of 174.60 and a beta of 0.89. The stock has a fifty day moving average of $52.03 and a two-hundred day moving average of $50.61. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.51 and a current ratio of 2.95.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. The firm had revenue of $310.10 million during the quarter, compared to analysts’ expectations of $287.65 million. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The firm’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.81 EPS. On average, analysts anticipate that LivaNova PLC will post 3.01 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.